Whitehawk Therapeutics, Inc. (WHWK) stock
WHWKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$3.13+0.05 (+1.62%)
Close on Nov 18, 2026Market cap $178.44MP/E –Yield –
Whitehawk Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Whitehawk Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $63.49M, down 22.5% year over year. For fiscal 2025 it was $90.96M, up 78.3% from the year before. The highest annual figure on record is $90.96M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $90.96M | +78.3% |
| FY2024 | Dec 31, 2024 | $51.03M | +4.3% |
| FY2023 | Dec 31, 2023 | $48.93M | +49.8% |
| FY2022 | Dec 31, 2022 | $32.66M | +66.0% |
| FY2021 | Dec 31, 2021 | $19.67M | +31.1% |
| FY2020 | Dec 31, 2020 | $15.01M | +17.0% |
| FY2019 | Dec 31, 2019 | $12.82M | -28.2% |
| FY2018 | Dec 31, 2018 | $17.85M | +47.0% |
| FY2017 | Dec 31, 2017 | $12.15M | +6.9% |
| FY2016 | Dec 31, 2016 | $11.37M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $12.89M | -73.6% |
| Q1 FY2026 | Mar 31, 2026 | $17.23M | +96.1% |
| Q4 FY2025 | Dec 31, 2025 | $19.02M | +32.6% |
| Q3 FY2025 | Sep 30, 2025 | $14.35M | +43.5% |
| Q2 FY2025 | Jun 30, 2025 | $48.81M | +272.8% |
| Q1 FY2025 | Mar 31, 2025 | $8.79M | -35.3% |
| Q4 FY2024 | Dec 31, 2024 | $14.35M | +12.4% |
| Q3 FY2024 | Sep 30, 2024 | $10.00M | -15.9% |
| Q2 FY2024 | Jun 30, 2024 | $13.09M | -1.7% |
| Q1 FY2024 | Mar 31, 2024 | $13.59M | +24.1% |
| Q4 FY2023 | Dec 31, 2023 | $12.77M | +36.3% |
| Q3 FY2023 | Sep 30, 2023 | $11.89M | +35.5% |
| Q2 FY2023 | Jun 30, 2023 | $13.32M | +72.3% |
| Q1 FY2023 | Mar 31, 2023 | $10.96M | +61.3% |
| Q4 FY2022 | Dec 31, 2022 | $9.37M | +29.7% |
| Q3 FY2022 | Sep 30, 2022 | $8.77M | +52.5% |
| Q2 FY2022 | Jun 30, 2022 | $7.73M | +153.7% |
| Q1 FY2022 | Mar 31, 2022 | $6.79M | +86.4% |
| Q4 FY2021 | Dec 31, 2021 | $7.23M | +35.7% |
| Q3 FY2021 | Sep 30, 2021 | $5.75M | +140.3% |
| Q2 FY2021 | Jun 30, 2021 | $3.05M | -14.2% |
| Q1 FY2021 | Mar 31, 2021 | $3.64M | +99.2% |
| Q4 FY2020 | Dec 31, 2020 | $5.32M | +150.0% |
| Q3 FY2020 | Sep 30, 2020 | $2.40M | -15.8% |
| Q2 FY2020 | Jun 30, 2020 | $3.55M | +56.7% |
| Q1 FY2020 | Mar 31, 2020 | $1.83M | -67.3% |
| Q4 FY2019 | Dec 31, 2019 | $2.13M | -59.4% |
| Q3 FY2019 | Sep 30, 2019 | $2.84M | -34.6% |
| Q2 FY2019 | Jun 30, 2019 | $2.26M | -46.5% |
| Q1 FY2019 | Mar 31, 2019 | $5.59M | +38.7% |
| Q4 FY2018 | Dec 31, 2018 | $5.25M | +38.8% |
| Q3 FY2018 | Sep 30, 2018 | $4.35M | +47.7% |
| Q2 FY2018 | Jun 30, 2018 | $4.23M | +33.4% |
| Q1 FY2018 | Mar 31, 2018 | $4.03M | +78.6% |
| Q4 FY2017 | Dec 31, 2017 | $3.78M | +89.7% |
| Q3 FY2017 | Sep 30, 2017 | $2.94M | -15.5% |
| Q2 FY2017 | Jun 30, 2017 | $3.17M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.26M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.99M | – |
| Q3 FY2016 | Sep 30, 2016 | $3.48M | – |
See a number that looks wrong?